New study reports aspirin increases prostate cancer survival
A new study has reported that aspiring increases cancer survival; it focused on whether aspirin reduced the risk of death from prostate cancer. Prostate cancer is the most common cancer occurring among men and the second most common cause of cancer deaths in men.
The study was published on August 25 in The Journal of Clinical Oncology by researchers at the University of Texas Southwestern Medical Center (Dallas, Texas), University of California, San Francisco (San Francisco, California), Brigham and Women's Hospital and Dana-Farber Cancer Institute (Boston, Massachusetts), and University of Chicago (Chicago, Illinois).
The researchers noted that experimental evidence suggests that anticoagulants such as aspirin may inhibit cancer growth and metastases; however, clinical data is limited. Therefore, they designed a study to investigate whether use of anticoagulants were associated with the risk of death from prostate cancer.
The study group was comprised of 5,955 men in the Cancer of the Prostate Strategic Urologic Research Endeavor database. They had localized adenocarcinoma of the prostate treated with radical prostatectomy or radiotherapy. Of the group, 2,175 (37%) were receiving anticoagulants (warfarin (Coumadin), clopidogrel (Plavix), enoxaparin (Lovenox), and/or aspirin). The risk of prostate cancer–specific mortality was compared between the anticoagulant and non-anticoagulant groups.